newsletter

IMO, a positive outcome from the comments made in these two paragraphs alone would see s/p skyrocket. Just hope there are no lurking vultures keeping the s/p artifically low. Last thing we want is a hostile takeover.

"Therapeutic midkine antibody program

Therapeutic antibodies continue to be the fastest growing area of drug development and can potentially provide a highly lucrative investment even in an early stage. Several preclinical stage deals have been done over the years, most recently an option and licensing deal between Celgene and Inhibrx valued at $500 million including
upfront, milestone and royalty payments."

"Midkine as early diagnostic and prognostic marker for cancer

Over the past year several diagnostic and pharma companies have expressed interest in midkine as an early cancer diagnostic marker. The Company’s strategy has previously been limited to out-licensing midkine on an indication
basis for the early diagnosis of cancer. In early 2012 we added strong prognostic data to our licensing package and we are currently talking to a dozen groups, mostly as to the utility of midkine as a prognostic agent."